HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. - Wikidata - wikimedia - TriplyDB

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

http://www.wikidata.org/entity/Q39368710

about

Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Targeting of erbB3 receptor to overcome resistance in cancer treatment Regulation of ERBB3/HER3 signaling in cancer An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Cellular effects of HER3-specific affibody molecules Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116 EGFR signaling in breast cancer: bad to the bone.E3 ubiquitin ligases in ErbB receptor quantity control.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice.New developments in the treatment of ovarian cancer--future perspectives.

P2860

Q24615472-BD83C3B6-8731-4BDE-A231-9A123054759D Q26824462-809EAA79-5040-4F2B-B989-89EA6174987F Q26864668-748B67E7-A66F-41A6-AA04-E79E2607A960 Q27024334-D658007D-214A-433B-848A-27C0257B930E Q27679463-7062840A-BFE7-4883-9F6C-037C1FB1B5BE Q28727774-DEA86C05-EA8B-4192-BEC2-8FD86D095D7C Q33412770-A6739E1D-370A-40C3-A586-E823B4288432 Q33559178-DA53B7A1-8D0F-4D0B-9072-0F657FB594A3 Q33891230-6B445C51-EA8C-4C13-9702-E9EC5CB8F1A3 Q34104165-C217DE5E-C563-445E-9B93-26F6FD5924AA Q34121278-130CCAD8-748B-40BB-9184-D1F305098AB1 Q34128962-4165B2E6-2872-493A-9402-C910F543F1FA Q34223890-9FC7EA82-2F73-4162-A520-C999284BDAA8 Q34348232-4A2B673D-9E19-402D-9484-2C02641229AB Q34349106-6D789E36-DA0A-4E6C-9D3A-3A4619C0A25A Q34355748-1E999D56-6703-4F65-858E-F50CE7D742CB Q34539092-2C132E93-1C69-4182-A7BB-53BD7938930B Q34735615-B2AA2C29-B5D9-4696-A33B-95267FC0D58C Q34949789-8DE682B8-C8F5-4410-A330-7755B041393E Q35145024-56AA6683-859A-4844-837D-0C2FB35AB4FF Q35409548-1307C02B-E427-4839-9CFA-3CB50538F776 Q35506684-157E79BE-FCE9-422E-BF86-B042399C29B5 Q35563891-7A3BAF87-A428-44A8-9DD3-C4D16BEF8C3A Q35584314-E250BD05-9AAD-4577-91A6-B6D4BBF4B45B Q35812023-3E5187F4-2774-4A60-9FFC-9A9FF13596B9 Q35812275-E36ADA23-A5DE-4711-92A2-B113EAAF8D6D Q35820920-98E04991-1D98-4EBE-8C23-A80EE54D9544 Q36106546-0160B321-3FE6-40A5-989E-23D559D9E64E Q36311874-78D44791-02D8-46D4-848D-1823D268ADC8 Q36547753-8D1DFCB8-4A73-418D-B2CD-99B3BEF7B838 Q36619622-F91EE186-8311-497E-A40A-63EA6A53A581 Q36670915-75EAA097-1C17-42D6-B704-B44B6C4FC0B5 Q36772036-EDD0B917-B986-4782-A68E-D5B08216AE4C Q36780754-6B78DBA4-28AF-4A25-86E5-AB2363B03064 Q36793441-29137D2E-BC69-49F3-93A2-7E79801102AB Q36797398-58E22A8B-8FAE-4BD2-93FA-A050DAEFBD0C Q37044197-5EFDF637-779C-4EE0-B1FB-4B9647AF2C49 Q37148772-2AEDA0CD-82A9-461F-BD80-A8E9B561059C Q37305409-3B535A10-34E8-443B-931E-3F162CAFF3D1 Q37332487-6DE6EE86-AEBC-40EB-86C2-0850EEF58E3B

P2860

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

http://www.wikidata.org/entity/Q39368710

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@en

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@nl

type

label

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@en

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@nl

prefLabel

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@en

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@nl

P1433

Q39368710-1066433E-04F6-4833-AED5-85145EBC6727

P1476

Q39368710-74701CC7-F911-44AA-B0A9-DF531712C735

P2093

Q39368710-56051193-9DD3-4F4D-A9A5-1C0B129962DC

Q39368710-B00C3C3D-DFAB-4246-96E1-2DEA6E39861E

Q39368710-DD1F2252-6E4A-461C-A327-936EC40F8195

P2860

Q39368710-015D8C23-8BEB-4044-ABC7-A70A4B0F6CFA

Q39368710-04B71B87-9172-4C83-9A4D-F63F43C837CF

Q39368710-094E8B24-BD2A-4700-82CB-3DF055B220FE

Q39368710-0ED5F68D-FB0C-4FA4-A4F5-5C44B8B6C192

Q39368710-1C44C210-05AF-4B1E-8878-E8F768D97FDA

Q39368710-235D399C-2B16-439F-B2D3-C52F64194708

Q39368710-238FADF5-E5B9-482C-B0A8-216FF07DC693

Q39368710-2887914C-0F8E-4404-8FEE-8C60C25D9A43

Q39368710-2AE6626E-797F-40C6-B021-6332AE2468F7

Q39368710-2C4AEBF1-6A7C-4938-8A5F-46E020170DE3

P304

Q39368710-8FE3EC89-3D29-42F5-83DC-ADFFE12CB512

P31

Q39368710-551F97B4-9482-4E36-9CA2-610B87CACAA0

P356

Q39368710-AE9CA0AC-67B5-4EF3-A863-3E97A362AD52

P407

Q39368710-31EBCFA6-B6DD-4D7B-ABAB-B0B6FEECE191

P433

Q39368710-8CFF16D5-BB5E-40D5-A84D-37AB293E53BD

P478

Q39368710-1D05B03E-8F16-4CE8-8CB4-29E87A945B16

P577

Q39368710-D800D12D-E448-466E-99BD-C08D7505A40F

P698

Q39368710-280DD19D-1A3E-4913-A185-E3579F993DF5

P932

Q39368710-68AF80FD-93ED-46C4-B09B-31B727D4A232

P356

1078-0432.CCR-09-1218

P1433

Clinical Cancer Research

P1476

HER3 comes of age: new insight ...... r biology, and cancer therapy.

@en

P2093

Dhara Amin

http://www.w3.org/2001/XMLSchema#string

Marcia R Campbell

http://www.w3.org/2001/XMLSchema#string

Mark M Moasser

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

A quantitative protein interaction network for the ErbB receptors using protein microarrays

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance

Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

Phosphotyrosine interactome of the ErbB-receptor kinase family

P304

1373-1383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1218

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20179223

http://www.w3.org/2001/XMLSchema#string

P932

2831167

http://www.w3.org/2001/XMLSchema#string